[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2655622T3 - Una formulación de fármaco de liberación retardada - Google Patents

Una formulación de fármaco de liberación retardada Download PDF

Info

Publication number
ES2655622T3
ES2655622T3 ES12166110.2T ES12166110T ES2655622T3 ES 2655622 T3 ES2655622 T3 ES 2655622T3 ES 12166110 T ES12166110 T ES 12166110T ES 2655622 T3 ES2655622 T3 ES 2655622T3
Authority
ES
Spain
Prior art keywords
polymeric material
core
neutralized
eudragit
release drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12166110.2T
Other languages
English (en)
Inventor
Roberto Carlos Bravo Gonzàles
Thomas Buser
Frédéric Jean-Claude Goutte
Abdul Waseh Basit
Felipe José Oliveira VARUM
Ana Cristina Freire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tillotts Pharma AG
Original Assignee
Tillotts Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46025554&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2655622(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tillotts Pharma AG filed Critical Tillotts Pharma AG
Application granted granted Critical
Publication of ES2655622T3 publication Critical patent/ES2655622T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Laminated Bodies (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Grain Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una formulación de fármaco de liberación retardada para administración oral con el fin de administrar un fármaco al colon de un sujeto, comprendiendo dicha formulación un núcleo y un recubrimiento para el núcleo, comprendiendo el núcleo un fármaco y comprendiendo el recubrimiento una capa externa y una capa interna, en la que la capa externa comprende una mezcla de un primer material polimérico que es susceptible al ataque de las bacterias del colon y un segundo material polimérico que tiene un umbral de pH a pH 6,5 o superior, y en la que la capa interna comprende un tercer material polimérico que es soluble en fluido intestinal, siendo dicho tercer material polimérico un polímero de ácido policarboxilico que está al menos parcialmente neutralizado, y en la que al menos el 10 % de los grupos de ácido carboxílico del polímero de ácido policarboxílico están en forma de aniones de carboxilato.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
En realizaciones preferidas, el segundo y tercer materiales poliméricos se basan en el mismo polímero de ácido policarboxílico, teniendo el tercer material polimérico un mayor grado de neutralización que el segundo material polimérico. Por ejemplo, para un polímero de ácido policarboxílico particular, el segundo material polimérico puede
5 estar en forma no neutralizada con el tercer material polimérico en forma parcial o totalmente neutralizada. Como alternativa, el segundo material polimérico puede estar en forma parcialmente neutralizada, con el tercer material polimérico también en forma parcialmente neutralizada (aunque parcialmente neutralizada en mayor medida), o en forma completamente neutralizada.
10 Los ejemplos de polímeros de ácido policarboxílico adecuados incluyen acetato ftalato de celulosa (CAP), acetato ftalato de polivinilo (PVAP), ftalato de hidroxipropilmetilcelulosa (HPMCP), acetato succinato de hidroxipropilmetilcelulosa (HPMC-AS), acetato trimelitato de celulosa (CAT), goma de xantano , alginatos y goma laca. Sin embargo, el polímero de ácido policarboxílico se selecciona preferiblemente de copolímeros de un ácido (met)acrílico y un alquilo de ácido (met)acrílico, por ejemplo, éster alquílico C1-4, y es particularmente adecuado un
15 copolímero de ácido metacrílico y éster metílico del ácido metacrílico. Tal polímero se conoce como un copolímero de poli(ácido metacrílico/metacrilato de metilo) o un "polimetacrilato". La relación entre los grupos de ácido carboxílicos y los grupos de éster metílico (la relación "ácido:éster") en estos copolimeros determina el pH al que el copolimero es soluble. La relación ácido:éster puede ser de aproximadamente 2:1 a aproximadamente 1:3, por ejemplo, aproximadamente 1:1 o, preferiblemente, aproximadamente 1:2. El peso molecular ("PM") de los
20 copolimeros aniónicos preferidos es habitualmente de aproximadamente 120.000 a 150,000 g/mol, preferiblemente aproximadamente 135.000. Los copolímeros preferidos incluyen Eudragit® L; Eudragit® S; Eudragit® FS; y Eudragit® L100-55.
Los polímeros ilustrativos se pueden usar como el tercer material polimérico en forma no neutralizada (siempre que
25 el umbral de pH del polímero sea menor que el umbral de pH del segundo material polimérico - véase más arriba) o se puede usar al menos parcialmente, más preferiblemente completamente, de forma neutralizada.
Los polímeros parcialmente neutralizados adecuados para su uso como el tercer material polimérico, y sus métodos de producción, son conocidos en la técnica, por ejemplo, a partir de los documentos US 2008/0200482 A y WO
30 2008/135090 A. Estos polímeros pueden ser completamente neutralizados por la adición de más base a las soluciones de recubrimiento.
En las realizaciones preferidas, el tercer material polimérico es un copolímero al menos parcialmente, preferiblemente completamente, neutralizado de ácido (met)acrílico y un éster alquílico C1-4 de ácido (met)acrílico.
35 En realizaciones particularmente preferidas, el tercer material polimérico es un copolímero completamente neutralizado de ácido (met)acrílico y éster metílico del ácido (met)acrílico, particularmente Eudragit® S.
Los inventores han observado que Eudragit® S completamente neutralizado es capaz de formar una película y es fácil y completamente soluble en agua independientemente de al menos el intervalo de pH encontrado en el
40 intestino, por ejemplo, pH de aproximadamente 5 a pH de aproximadamente 8. Eudragit® S completamente neutralizado es particularmente preferido para su uso como el tercer material polimérico en la presente invención.
Se pueden usar mezclas de materiales de polímeros de formación de película según sea apropiado. Los componentes poliméricos en dichas mezclas pueden ser polímeros aniónicos o una mezcla de polímeros aniónicos y
45 no iónicos. Un ejemplo de una mezcla adecuada incluirá una mezcla, por ejemplo, una mezcla 1:1, de Eudragit® L y Eudragit® S, y una mezcla, por ejemplo, una mezcla 1:1, de Eudragit® S y HPMC. Sin embargo, se prefiere el uso de un material polimérico de formación de película particular en solitario, por ejemplo, un copolímero de poli(ácido metacrílico/metacrilato de metilo) y Eudragit® S en particular.
50 Base
En realizaciones preferidas, la capa interna comprende al menos una base. El objetivo de la base es proporcionar un entorno alcalino en la parte inferior de la capa externa una vez que el fluido intestinal comienza a penetrar en la capa externa. Sin quedar ligando a ninguna teoría particular, los inventores creen que el entorno alcalino facilita la
55 desintegración de la capa externa ya que el pH del entorno alcalino está por encima del umbral de pH del segundo material polimérico, acelerando de este modo la liberación del fármaco de la formulación una vez el recubrimiento externo se disuelve y/o se desintegra.
En principio, se puede usar cualquier base farmacológicamente aceptable. Las bases adecuadas incluyen bases
9
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17

Claims (1)

  1. imagen1
    imagen2
ES12166110.2T 2012-04-30 2012-04-30 Una formulación de fármaco de liberación retardada Active ES2655622T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12166110.2A EP2659881B1 (en) 2012-04-30 2012-04-30 A delayed release drug formulation

Publications (1)

Publication Number Publication Date
ES2655622T3 true ES2655622T3 (es) 2018-02-20

Family

ID=46025554

Family Applications (6)

Application Number Title Priority Date Filing Date
ES12166110.2T Active ES2655622T3 (es) 2012-04-30 2012-04-30 Una formulación de fármaco de liberación retardada
ES17157257T Active ES2987408T3 (es) 2012-04-30 2012-04-30 Una formulación de fármaco de liberación retardada
ES13719543T Active ES2714448T3 (es) 2012-04-30 2013-04-29 Una formulación de fármaco de liberación retardada
ES13723033T Active ES2761341T3 (es) 2012-04-30 2013-04-29 Una formulación de fármaco de liberación retardada
ES17188821T Active ES2720258T3 (es) 2012-04-30 2013-04-29 Una formulación de fármaco de liberación retardada
ES17156227.5T Active ES2673931T3 (es) 2012-04-30 2013-04-29 Una formulación de fármaco de liberación retardada

Family Applications After (5)

Application Number Title Priority Date Filing Date
ES17157257T Active ES2987408T3 (es) 2012-04-30 2012-04-30 Una formulación de fármaco de liberación retardada
ES13719543T Active ES2714448T3 (es) 2012-04-30 2013-04-29 Una formulación de fármaco de liberación retardada
ES13723033T Active ES2761341T3 (es) 2012-04-30 2013-04-29 Una formulación de fármaco de liberación retardada
ES17188821T Active ES2720258T3 (es) 2012-04-30 2013-04-29 Una formulación de fármaco de liberación retardada
ES17156227.5T Active ES2673931T3 (es) 2012-04-30 2013-04-29 Una formulación de fármaco de liberación retardada

Country Status (41)

Country Link
US (6) US10226430B2 (es)
EP (6) EP2659881B1 (es)
JP (2) JP6621662B2 (es)
KR (6) KR20190127986A (es)
CN (5) CN104302274A (es)
AR (1) AR090898A1 (es)
AU (4) AU2013255913B2 (es)
BR (3) BR112014026933B1 (es)
CA (4) CA3052460C (es)
CL (2) CL2014002796A1 (es)
CO (2) CO7141433A2 (es)
CR (4) CR20190246A (es)
CU (1) CU24304B1 (es)
CY (4) CY1120215T1 (es)
DK (5) DK2659881T3 (es)
EA (2) EA032514B1 (es)
ES (6) ES2655622T3 (es)
GE (4) GEP201706753B (es)
HR (2) HRP20180068T1 (es)
HU (5) HUE036187T2 (es)
JO (6) JOP20200144A1 (es)
LT (5) LT2659881T (es)
ME (2) ME03641B (es)
MX (3) MX367127B (es)
MY (3) MY169161A (es)
NO (1) NO2659881T3 (es)
NZ (3) NZ629260A (es)
PE (3) PE20190625A1 (es)
PH (2) PH12014502340B1 (es)
PL (5) PL2659881T3 (es)
PT (5) PT2659881T (es)
RS (5) RS56839B1 (es)
SA (2) SA113340508B1 (es)
SG (2) SG11201406798WA (es)
SI (5) SI2659881T1 (es)
SM (5) SMT201800095T1 (es)
TN (2) TN2014000441A1 (es)
TR (3) TR201905226T4 (es)
TW (3) TWI618547B (es)
UY (1) UY34772A (es)
WO (2) WO2013164316A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2655622T3 (es) 2012-04-30 2018-02-20 Tillotts Pharma Ag Una formulación de fármaco de liberación retardada
CU24342B1 (es) * 2012-04-30 2018-05-08 Tillotts Pharma Ag Formulación de fármaco de liberación retardada
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
SG11201506653WA (en) * 2013-02-22 2015-09-29 Zeria Pharm Co Ltd Enteric coated tablet
NZ717159A (en) 2013-10-29 2019-06-28 Tillotts Pharma Ag A delayed release drug formulation
EA030615B1 (ru) 2013-12-24 2018-08-31 Сентисс Фарма Прайвет Лимитед Офтальмологический раствор бримонидина для местного применения
ES2898930T3 (es) 2015-06-01 2022-03-09 Xeno Biosciences Inc Composiciones para usar en la modulación de la microbiota intestinal y el manejo del peso
EP4119539A1 (en) 2015-09-23 2023-01-18 XWPharma Ltd. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
CN105816883B (zh) * 2016-02-03 2018-12-14 华南师范大学 一种负载抗癌药物姜黄素的益生菌叶酸靶向载体及其制备方法
EP3257501A1 (en) 2016-06-14 2017-12-20 Tillotts Pharma AG Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating
WO2018102469A1 (en) * 2016-11-30 2018-06-07 Xeno Biosciences Inc. Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota
EP3768302A4 (en) * 2018-03-20 2021-12-15 Synthetic Biologics, Inc. INTESTINAL ALKALINE PHOSPHATASE FORMULATIONS
WO2019183472A1 (en) * 2018-03-23 2019-09-26 Palatin Technologies, Inc. Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery
CA3120619A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP3662898A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
EP3662902B1 (en) * 2018-12-07 2024-07-31 Tillotts Pharma AG Colonic drug delivery formulation
EP3662901B1 (en) * 2018-12-07 2025-01-01 Tillotts Pharma AG Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing
EP3662900A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
ES2906316T3 (es) * 2018-12-10 2022-04-18 Aphaia Ip Ag Formas farmacéuticas de dosificación oral para el tratamiento de trastornos metabólicos y enfermedades relacionadas mediante la liberación orquestada de enterocinas
WO2020257017A1 (en) 2019-06-18 2020-12-24 Progenity, Inc. Ingestible device with component capable of residing in the gastrointestinal tract
CN114340615A (zh) * 2019-08-12 2022-04-12 麻省理工学院 用于施用治疗剂的制品和方法
FR3102931B1 (fr) * 2019-11-13 2021-12-24 Ethypharm Sa Procédé de fabrication d’une composition pharmaceutique à administration orale et à délivrance colonique
CN115461046A (zh) * 2019-11-13 2022-12-09 爱的发制药集团 用于生产具有结肠递送的口服施用药物组合物的方法
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN111567678A (zh) * 2020-05-11 2020-08-25 四川英格瑞生物科技有限公司 无抗畜类肠道保健剂及其制备方法
US11426353B2 (en) * 2020-06-24 2022-08-30 13400719 Canada Inc. Composite coating for an active agent
CN118806729A (zh) * 2024-06-18 2024-10-22 海南合瑞制药股份有限公司 美沙拉秦肠溶缓释微丸及其制备方法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5291419A (en) * 1976-01-28 1977-08-01 Fuji Yakuhin Kogyo Kk Coloring image forming photosensitive sheet
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
DE4217920C2 (de) * 1992-05-30 1996-05-09 Goldwell Gmbh Verfahren zur Herstellung von pulverförmigen Mitteln zum Blondieren von menschlichen Haaren
EP0667148B1 (en) * 1992-11-06 2002-07-03 Hisamitsu Pharmaceutical Co., Inc. Peroral pharmaceutical preparation releasable in lower digestive tract
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
FR2711525B1 (fr) 1993-10-29 1996-01-12 Virbac Laboratoires Forme Galénique à administration orale pour animaux, son procédé de préparation et ses applications.
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
CN1239425A (zh) * 1996-11-15 1999-12-22 普罗克特和甘保尔公司 供结肠释放的具有多层肠溶聚合物包衣的药剂
CA2236605A1 (en) * 1997-05-09 1998-11-09 Yves Duccini Scale inhibitors
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
ATE238797T1 (de) * 1999-12-16 2003-05-15 Medinfar Produtos Farmaceutico Piroxicam enthaltende gastrointestinale zubereitung aus merheren einheiten bestehend
DE10013029A1 (de) * 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
FI20000780A (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
US6939920B2 (en) 2001-01-08 2005-09-06 The Goodyear Tire & Rubber Company Tire sidewall compounds having improved flex fatigue and tread compound having improved tear strength
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
CN1293867C (zh) 2001-05-25 2007-01-10 爱诗爱诗制药株式会社 药物复合制剂
US7183321B2 (en) 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
FR2842736B1 (fr) * 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
EP1560597A4 (en) * 2002-10-29 2007-06-27 Pharmacia Corp DIFFERENTIALLY EXPRESSED GENES INVOLVED IN CANCER, POLYPEPTIDES CODED THEREWITH, AND METHODS OF USING GENES
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
AU2002361495A1 (en) 2002-12-24 2004-07-22 Lupin Limited Enteric coated fluoxetine composition
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
MXPA06009991A (es) * 2004-03-03 2007-04-10 Teva Pharma Una composicion farmaceutica estable que comprende un farmaco labil acido.
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP1904039A2 (en) 2005-06-20 2008-04-02 Cadila Healthcare Ltd. Controlled release dosage formulation of duloxetine
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
JP4984695B2 (ja) 2006-07-11 2012-07-25 株式会社明電舎 色素増感型太陽電池及びその製造方法
SK287622B6 (sk) * 2006-07-25 2011-04-05 Peter Pap Odkladacia schránka
US20090175935A1 (en) 2006-08-14 2009-07-09 Torrent Research Ltd. Pharmaceutical compositions of duloxetine
US20100055173A1 (en) * 2006-10-10 2010-03-04 Adel Penhasi Release of statins in the intestine
US20100179170A1 (en) * 2006-12-05 2010-07-15 Lisa Claire Du Toit Heterogeneously configured multiparticulate gastrointestinal drug delivery system
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
JP2008214249A (ja) 2007-03-02 2008-09-18 Takeda Chem Ind Ltd 製剤における溶出改善方法および溶出性の改善された製剤
AU2008230364A1 (en) * 2007-03-26 2008-10-02 Teikoku Seiyaku Co., Ltd. Oral pharmaceutical preparation for colon-specific delivery
BRPI0721654B8 (pt) 2007-05-07 2022-07-05 Evonik Roehm Gmbh formas de dosagem sólida compreendendo um revestimento entérico com liberação acelerada do fármaco, seu método de fabricação e uso
US20090162434A1 (en) 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
US20110177164A1 (en) * 2008-10-06 2011-07-21 Gopal Rajan Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
CN108096209A (zh) 2009-06-15 2018-06-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
EP2486918A4 (en) * 2009-10-09 2014-02-26 Yungjin Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITION WITH BOTH IMMEDIATE AND DELAYED RELEASE
EP2384746A3 (en) 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
WO2012075015A2 (en) 2010-11-29 2012-06-07 Dr. Reddy's Laboratories Ltd. Oral metronidazole pharmaceutical compositions
CA2885680C (en) 2011-09-07 2022-10-04 Roland Saur-Brosch Formulation for the controlled release of one or several substances in the digestive tract of a mammal.
CN102319218B (zh) 2011-09-22 2014-10-01 贝沃特医药技术(上海)有限公司 一种治疗肠道疾病的药物缓控释微粒制剂及其制备方法
ES2655622T3 (es) 2012-04-30 2018-02-20 Tillotts Pharma Ag Una formulación de fármaco de liberación retardada
US9844436B2 (en) 2012-10-26 2017-12-19 Edwards Lifesciences Corporation Aortic valve and conduit graft implant tool
NZ717159A (en) 2013-10-29 2019-06-28 Tillotts Pharma Ag A delayed release drug formulation

Also Published As

Publication number Publication date
NZ629262A (en) 2017-01-27
SI2844222T1 (sl) 2020-02-28
SI3189830T1 (en) 2018-08-31
CA2871016A1 (en) 2013-11-07
CN106983735A (zh) 2017-07-28
CO7141433A2 (es) 2014-12-12
ES2987408T3 (es) 2024-11-14
US9364440B2 (en) 2016-06-14
JOP20200145B1 (ar) 2023-09-17
CA2871016C (en) 2023-03-21
SA115370043B1 (ar) 2016-05-24
EP3189830B1 (en) 2018-05-23
US9814681B2 (en) 2017-11-14
KR20190127984A (ko) 2019-11-13
HUE043238T2 (hu) 2019-08-28
HRP20180965T1 (hr) 2018-08-10
HUE042833T2 (hu) 2019-07-29
KR20200075024A (ko) 2020-06-25
ME03364B (me) 2019-10-20
CA2871017A1 (en) 2013-11-07
GEP201706753B (en) 2017-10-25
LT3189830T (lt) 2018-07-10
CN104302274A (zh) 2015-01-21
JOP20200144A1 (ar) 2017-06-16
TWI618547B (zh) 2018-03-21
KR20150004911A (ko) 2015-01-13
EA032811B1 (ru) 2019-07-31
PL2659881T3 (pl) 2018-05-30
TWI705833B (zh) 2020-10-01
US10226430B2 (en) 2019-03-12
SI3278792T1 (sl) 2019-06-28
US20170266117A1 (en) 2017-09-21
JOP20200145A1 (ar) 2022-10-30
SMT201800360T1 (it) 2018-09-13
CO7151506A2 (es) 2014-12-29
EP2659881B1 (en) 2017-11-29
HRP20180068T1 (hr) 2018-03-23
DK2659881T3 (en) 2018-02-05
GEP201706758B (en) 2017-10-25
EP2844220A1 (en) 2015-03-11
PH12014502340A1 (en) 2014-12-22
RS57431B1 (sr) 2018-09-28
JOP20200146B1 (ar) 2023-09-17
RS56839B1 (sr) 2018-04-30
CR20140486A (es) 2015-01-19
BR122019022551B1 (pt) 2022-07-19
CL2014002796A1 (es) 2015-02-06
PH12014502339A1 (en) 2014-12-22
CA3052460A1 (en) 2013-11-07
PL3189830T3 (pl) 2018-11-30
CN110200949A (zh) 2019-09-06
AU2017210571B2 (en) 2018-11-29
CN110237056A (zh) 2019-09-17
KR102177773B1 (ko) 2020-11-12
NO2659881T3 (es) 2018-04-28
BR112014026935A2 (pt) 2017-06-27
CY1122475T1 (el) 2021-01-27
PT3278792T (pt) 2019-05-23
TN2014000441A1 (en) 2016-03-30
EP3187171C0 (en) 2024-09-25
AR090898A1 (es) 2014-12-17
BR112014026933A2 (pt) 2017-06-27
CR20190246A (es) 2019-09-03
EP3278792B1 (en) 2019-02-20
US20170035698A1 (en) 2017-02-09
PT2659881T (pt) 2018-01-29
HUE036187T2 (hu) 2018-06-28
TW201343202A (zh) 2013-11-01
JOP20200147A1 (ar) 2022-10-30
ES2761341T3 (es) 2020-05-19
TN2014000442A1 (en) 2016-03-30
PE20150129A1 (es) 2015-02-13
MX366677B (es) 2019-07-19
ME03641B (me) 2020-07-20
HUE046628T2 (hu) 2020-03-30
TW202037370A (zh) 2020-10-16
PL2844222T3 (pl) 2020-03-31
PH12014502339B1 (en) 2014-12-22
CA3052460C (en) 2022-06-07
JP2015515964A (ja) 2015-06-04
LT2844222T (lt) 2019-12-27
CY1121609T1 (el) 2020-05-29
EP3278792A1 (en) 2018-02-07
JP2015515965A (ja) 2015-06-04
PT3189830T (pt) 2018-10-19
SMT201900215T1 (it) 2019-05-10
CN104271113B (zh) 2019-03-22
AU2017210577A1 (en) 2017-08-24
US20150125525A1 (en) 2015-05-07
CY1120492T1 (el) 2019-07-10
PL3278792T3 (pl) 2019-09-30
CU20140123A7 (es) 2015-02-26
MX367127B (es) 2019-08-06
MY169161A (en) 2019-02-19
GEP201706759B (en) 2017-10-25
JOP20200148A1 (ar) 2022-10-30
US20150132380A1 (en) 2015-05-14
AU2013255914B2 (en) 2017-08-31
US20200214987A1 (en) 2020-07-09
SMT201900252T1 (it) 2019-07-11
CN104271113A (zh) 2015-01-07
KR20200073296A (ko) 2020-06-23
RS59697B1 (sr) 2020-01-31
LT2844220T (lt) 2019-04-10
BR112014026933B1 (pt) 2022-07-19
EP3189830A1 (en) 2017-07-12
JO3574B1 (ar) 2020-07-05
NZ725409A (en) 2018-05-25
JP6621661B2 (ja) 2019-12-18
HUE037702T2 (hu) 2018-09-28
AU2017210571A1 (en) 2017-08-24
CR20190245A (es) 2019-07-29
US10272048B2 (en) 2019-04-30
US11534406B2 (en) 2022-12-27
RS58625B1 (sr) 2019-05-31
KR20190127986A (ko) 2019-11-13
NZ629260A (en) 2017-01-27
LT3278792T (lt) 2019-05-10
PT2844222T (pt) 2019-12-30
EA201491781A1 (ru) 2014-12-30
EP2844220B1 (en) 2019-01-23
US20140056980A1 (en) 2014-02-27
JOP20200146A1 (ar) 2022-10-30
EA201491783A1 (ru) 2014-12-30
ES2720258T3 (es) 2019-07-19
SMT201800095T1 (it) 2018-03-08
WO2013164316A1 (en) 2013-11-07
EP2659881A1 (en) 2013-11-06
SMT202000014T1 (it) 2020-03-13
UY34772A (es) 2013-11-29
DK3189830T3 (en) 2018-07-16
MX362529B (es) 2019-01-23
PE20142442A1 (es) 2015-01-28
MY190392A (en) 2022-04-20
TR201903569T4 (tr) 2019-04-22
TW201720430A (zh) 2017-06-16
CU24304B1 (es) 2018-01-10
CN110200949B (zh) 2021-11-16
PT2844220T (pt) 2019-03-27
SA113340508B1 (ar) 2016-02-07
SI2659881T1 (en) 2018-03-30
CY1120215T1 (el) 2018-12-12
SI2844220T1 (sl) 2019-05-31
EA032514B1 (ru) 2019-06-28
AU2013255914A1 (en) 2014-11-13
AU2013255913B2 (en) 2017-08-31
SG11201406798WA (en) 2014-11-27
CR20140485A (es) 2015-01-19
PH12014502340B1 (en) 2014-12-22
KR102104070B1 (ko) 2020-04-24
AU2013255913A1 (en) 2014-11-13
DK2844220T3 (en) 2019-04-08
GEP201706736B (en) 2017-09-25
MX2014012888A (es) 2015-04-13
MY169088A (en) 2019-02-15
EP3187171A1 (en) 2017-07-05
TR201905226T4 (tr) 2019-05-21
KR102198621B1 (ko) 2021-01-06
PL2844220T3 (pl) 2019-06-28
LT2659881T (lt) 2018-02-12
EP2844222A1 (en) 2015-03-11
CN110237056B (zh) 2022-03-08
PE20190625A1 (es) 2019-04-26
RS58735B1 (sr) 2019-06-28
MX2014012887A (es) 2015-05-08
WO2013164315A1 (en) 2013-11-07
CL2014002795A1 (es) 2015-02-13
JOP20200148B1 (ar) 2023-09-17
JOP20200147B1 (ar) 2023-09-17
KR102102198B1 (ko) 2020-04-21
CA3080035A1 (en) 2013-11-07
DK3278792T3 (da) 2019-05-06
TWI700102B (zh) 2020-08-01
AU2017210577B2 (en) 2018-11-29
EP2844222B1 (en) 2019-11-13
US11517534B2 (en) 2022-12-06
TR201809416T4 (tr) 2018-07-23
ES2673931T3 (es) 2018-06-26
JP6621662B2 (ja) 2019-12-18
SG11201406799XA (en) 2014-11-27
ES2714448T3 (es) 2019-05-28
KR20150004910A (ko) 2015-01-13
DK2844222T3 (da) 2019-12-09
EP3187171B1 (en) 2024-09-25

Similar Documents

Publication Publication Date Title
ES2655622T3 (es) Una formulación de fármaco de liberación retardada
ES2832699T3 (es) Cápsulas recubiertas de liberación modificada
EA201390981A1 (ru) Разрушающаяся во рту таблетка
RU2019121301A (ru) Композиции, включающие электрогидродинамически полученные волокна, для нанесения заданных доз активного вещества на кожу или слизистую оболочку
AR103981A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención
RU2015110825A (ru) Устойчивая к действию желудочного сока фармацевтическая или нутрицевтическая композиция со стойкостью к влиянию этанола
JP2016510022A5 (es)
JP2013544259A5 (es)
RU2013141534A (ru) Составы l-ментола, состоящие из множества частиц, и связанные с ними способы
AR065539A1 (es) Composiciones farmaceuticas que comprenden nanoparticulas que comprenden polimeros entericos y caseina
EA201690596A1 (ru) Лекарственный препарат с отсроченным высвобождением
ES2721849T3 (es) Forma oral sólida dotada de un doble perfil de liberación que comprende multipartículas
CN108367078A (zh) 医药微丸的干粉包衣组合物
RU2015140119A (ru) Таблетка, покрытая кишечнорастворимым покрытием
ES2831321T3 (es) Cápsulas recubiertas de liberación modificada
AR102228A1 (es) Una formulación de metformina de liberación sostenida y un método de preparación de la misma
HRP20190727T1 (hr) Formulacija odgođenog otpuštanja lijeka
RU2012140651A (ru) Фармацевтический или нутрицевтический состав
JP2017506265A5 (es)
NZ705802A (en) Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it.
AR087032A1 (es) Composiciones de capsulas de gelatina y metodos para fabricarlas
RU2016118775A (ru) Фармацевтическая композиция с контролируемым высвобождением, основанная на прионовой кислоте
HRP20191493T1 (hr) Oblici doze za oralnu primjenu aktivnih supstanci
Borumand et al. Comparison of mucoadhesive strength of different polymers in vagino-adhesive propranolol hydrochloride film
AU2009220116A1 (en) Controlled release drug delivery systems and pharmaceutical compositions formed therewith